Keeping pace with change
The availability of transformative technology provides an opportunity to modernize the current approach to regulatory submissions. Current methods for data exchange and information exchange between life sciences companies and global health authorities have not kept pace with advancements in information technology.
Accumulus aims to provide a global collaboration platform to consolidate interactions and exchange near real-time data globally to accelerate medicines to patients.
Cost to bring a pharmaceutical product to market in 20211
$2B
an increase of
$710M
from 2013
A focus on overcoming unmet needs
associated with drug lag1
“Filing a New Drug Application may have shifted from driving a truckload of paper to the relevant regulatory authority, to FedEx-ing a CD-ROM, to uploading a set of PDFs through the Electronic Submissions Gateway, but the underlying processes remain little changed. It’s long past time to play catchup —it’s time for a moon shot.”
– Francisco Nogueira, Chief Executive Officer, at Accumulus Synergy
Reference:
1. Nurturing growth: measuring the return from pharmaceutical innovation 2021. Deloitte. Available at: https://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/measuring-return-from-pharmaceutical-innovation.html. Accessed February 9, 2022.